Robert Wesolowski, MD
Academic Title: Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forI am a medical oncologist specializing in treating patients with breast cancer, including female and male breast cancers, ductal breast carcinomas, lobular carcinomas, medullary carcinomas and inflammatory breast cancers. I chose a career in oncology because I am passionate about understanding cancer biology and using this knowledge to develop treatments that may lead to a cure. As a clinical professor of Internal Medicine and a member of the Translational Therapeutics Program at the OSUCCC – James, my research is focused on breast cancer immunology. I study how the body’s natural immune system responds to cancer, with the goal of improving and expanding the use of immunotherapies to shrink tumors. I am currently serving as a principal investigator on several phase I trials that are exploring potential therapies to fight breast cancer and other solid tumors. My research has been published in many peer-reviewed journals including the Journal of Clinical Oncology, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, Breast Cancer Research and Treatment, and Therapeutic Advances in Medical Oncology. I am proud to encourage and mentor other clinician-scientists in my role leading the Phase I Disease Research group at The James. We support other investigators who are working on early phase clinical trials to test novel anti-cancer therapies. I was honored to be recognized with the Bertha A. Bouroncle Distinguished Teacher Award from The Ohio State University, and a Physician "Champion of Nursing" Excellence Award from The James. In addition, I am a recipient of The James Physician Champion Award, which recognizes exceptional patient care in oncology. I have been named to the Castle Connolly Top Doctors list and recognized by Columbus Business First as one of central Ohio’s best doctors of medical oncology and hematology.
Clinical Expertise
More info for- Breast Cancer
- Hereditary Breast and Ovarian Cancer Syndrome
Research Interests
More info for- Sarcoma
- Stomach Neoplasms
- Carcinoma
- Prostatic Neoplasms
- Neoplasms
- Neutropenia
- Breast Neoplasms
- Hypersensitivity
- Neoplasm Metastasis
- Carcinoma, Hepatocellular
Where I See Patients
More info forStefanie Spielman Comprehensive Breast Center
1145 Olentangy River Road Columbus, Ohio 43212 800-293-5066 Location InformationEducation & Training
More info forFellowship - Hematology & Oncology
- Cleveland Clinic Foundation
9500 Euclid Ave, Cleveland, OH
Internship - Internal Medicine
- Cleveland Clinic Foundation
9500 Euclid Ave, Cleveland, OH
Residency - Internal Medicine
- Cleveland Clinic Foundation
9500 Euclid Ave, Cleveland, OH
Medical School
- SUNY Downstate Medical Center College of Nursing
450 Clarkson Ave Ofc Oftheregistrar, Brooklyn, NY
- Cleveland Clinic Foundation
Academic Office & Contact Information
More info forAcademic Office:
Lincoln Tower 1310D
1800 Cannon Dr
Columbus, Ohio 43210Phone:
614-366-1525Email:
wesolowski.12@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forSeptember 12, 2024A first-in-human phase 1 study of BXQ-350, a first-in-class sphingolipid metabolism regulator, in patients with advanced/recurrent solid tumors or high-grade gliomas.
Rixe O, Villano JL, Wesolowski R, Noonan AM, Puduvalli VK, Wise-Draper TM, Curry R, Yilmaz E, Cruze C, Ogretmen B, Tapolsky G, Takigiku R
Clin Cancer Res
July 3, 2024Identifying Key Genes Involved in Axillary Lymph Node Metastasis in Breast Cancer Using Advanced RNA-Seq Analysis: A Methodological Approach with GLMQL and MAS.
Rezapour M, Wesolowski R, Gurcan MN
Int J Mol Sci
June 19, 2024The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer.
Johnson KCC, Ni A, Quiroga D, Pariser AC, Sudheendra PK, Williams NO, Sardesai SD, Cherian M, Stover DG, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R
NPJ Breast Cancer
June 1, 2024Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.
Sukumar JS, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover DG, Gatti-Mays M, Pariser A, Sudheendra P, George MA, Lustberg M
Cancer Med
May 30, 2024Chemotherapy-induced gut microbiome disruption, inflammation, and cognitive decline in female patients with breast cancer.
Otto-Dobos LD, Grant CV, Lahoud AA, Wilcox OR, Strehle LD, Loman BR, Adarkwah Yiadom S, Seng MM, Halloy N, Russart KLG, Carpenter KM, Dawson E, Sardesai SD, Williams NO, Gatti-Mays ME, Stover DG, Sudheendra PK, Wesolowski R, Kiecolt-Glaser JK, Bailey MT, Andridge RR, Pyter LM
Brain Behav Immun
April 1, 2024Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, Specht JM, Dees EC, Kabos P, Suzuki S, Mutka SC, Sullivan BF, Gorbatchevsky I, Wesolowski R
Lancet Oncol
January 1, 2024An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.
Quiroga D, Wesolowski R, Zelinskas S, Pinette A, Benner B, Schwarz E, Savardekar H, Johnson C, Stiff A, Yu L, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson WE
Cancer Control
December 19, 2023PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study.
Ferrarotto R, Swiecicki PL, Zandberg DP, Baiocchi RA, Wesolowski R, Rodriguez CP, McKean M, Kang H, Monga V, Nath R, Palmisiano N, Babbar N, Sun W, Hanna GJ
Oral Oncol
November 28, 2023Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase.
Savardekar H, Allen C, Jeon H, Li J, Quiroga D, Schwarz E, Wu RC, Zelinskas S, Lapurga G, Abreo A, Stiff A, Shaffer J, Blaser BW, Old M, Wesolowski R, Xin G, Kendra KL, Chung D, Carson WE
Mol Cancer Res
November 22, 2023Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients.
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi CL, Ruddy KJ, Cathcart-Rake E, Trovato S, Dulmage B
Support Care Cancer
October 14, 2023Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls.
Johnson KC, Grimm M, Sukumar J, Schnell PM, Park KU, Stover DG, Jhawar SR, Gatti-Mays M, Wesolowski R, Williams N, Sardesai S, Pariser A, Sudheendra P, Tozbikian G, Ramaswamy B, Doto D, Cherian MA
Breast
October 1, 2023First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
Leidner R, Conlon K, McNeel DG, Wang-Gillam A, Gupta S, Wesolowski R, Chaudhari M, Hassounah N, Lee JB, Ho Lee L, O'Keeffe JA, Lewis N, Pavlakis GN, Thompson JA
J Immunother Cancer
September 4, 2023Depression, Inflammation, and Intestinal Permeability: Associations with Subjective and Objective Cognitive Functioning throughout Breast Cancer Survivorship.
Madison AA, Andridge R, Kantaras AH, Renna ME, Bennett JM, Alfano CM, Povoski SP, Agnese DM, Lustberg M, Wesolowski R, Carson WE, Williams NO, Reinbolt RE, Sardesai SD, Noonan AM, Stover DG, Cherian MA, Malarkey WB, Kiecolt-Glaser JK
Cancers (Basel)
August 1, 2023Missing Components of Receptor Status Among Women With Invasive Breast Cancer.
Stephens JA, Fisher JL, Wesolowski R, Paskett ED
JAMA Netw Open
June 24, 2023The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.
Johnson KCC, Goldstein D, Tharakan J, Quiroga D, Kassem M, Grimm M, Miah A, Vargo C, Berger M, Sudheendra P, Pariser A, Gatti-Mays ME, Williams N, Stover D, Sardesai S, Wesolowski R, Ramaswamy B, Tozbikian G, Schnell PM, Cherian MA
Oncol Ther
May 12, 2023Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors.
Tsimberidou AM, Verschraegen CF, Wesolowski R, Shia CS, Hsu P, Pearce TE
Br J Cancer
March 24, 2023Incidence, Clinicopathologic Features, HER2 FISH Profile and Oncotype DX Results of HER2-low Breast Cancers: Experience from a Single Academic Center.
Hu Y, Jones D, Zhao W, Tozbikian G, Wesolowski R, Parwani AV, Li Z
Mod Pathol
March 22, 2023Conflicts hurt: social stress predicts elevated pain and sadness after mild inflammatory increases.
Madison AA, Renna M, Andridge R, Peng J, Shrout MR, Sheridan J, Lustberg M, Ramaswamy B, Wesolowski R, Williams NO, Noonan AM, Reinbolt RE, Stover DG, Cherian MA, Malarkey WB, Kiecolt-Glaser JK
Pain
January 1, 2023A troubled heart: Mood disorder history longitudinally predicts faster cardiopulmonary aging in breast cancer survivorship.
Madison AA, Filatov M, Andridge R, Haas G, Povoski SP, Agnese DM, Lustberg M, Reinbolt RE, Wesolowski R, Williams NO, Malarkey WB, Kiecolt-Glaser JK
PLoS One
January 1, 2023BCR-Net: A deep learning framework to predict breast cancer recurrence from histopathology images.
Su Z, Niazi MKK, Tavolara TE, Niu S, Tozbikian GH, Wesolowski R, Gurcan MN
PLoS One
January 1, 2023Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
Williams NO, Quiroga D, Johnson C, Brufsky A, Chambers M, Bhattacharya S, Patterson M, Sardesai SD, Stover D, Lustberg M, Noonan AM, Cherian M, Bystry DM, Hill KL, Chen M, Phelps MA, Grever M, Stephens JA, Ramaswamy B, Carson WE, Wesolowski R
Ther Adv Med Oncol
December 30, 2022A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013.
Ademuyiwa FO, Gao F, Street CR, Chen I, Northfelt DW, Wesolowski R, Arora M, Brufsky A, Dees EC, Santa-Maria CA, Connolly RM, Force J, Moreno-Aspitia A, Herndon JM, Carmody M, Davies SR, Larson S, Pfaff KL, Jones SM, Weirather JL, Giobbie-Hurder A, Rodig SJ, Liu Z, Hagemann IS, Sharon E, Gillanders WE
NPJ Breast Cancer
November 14, 2022Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses' health study.
Asad S, Damicis A, Heng YJ, Kananen K, Collier KA, Adams EJ, Kensler KH, Baker GM, Wesolowski R, Sardesai S, Gatti-Mays M, Ramaswamy B, Eliassen AH, Hankinson SE, Tabung FK, Tamimi RM, Stover DG
Breast Cancer Res
October 5, 2022Typhoid Vaccine Does Not Impact Feelings of Social Connection or Social Behavior in a Randomized Crossover Trial Among Middle-Aged Female Breast Cancer Survivors.
Madison AA, Way B, Ratner K, Renna M, Andridge R, Peng J, Rosie Shrout M, Sheridan J, Lustberg M, Ramaswamy B, Wesolowski R, VanDeusen JB, Williams NO, Sardesai SD, Noonan AM, Reinbolt RE, Stover DG, Cherian MA, Malarkey WB, Kiecolt-Glaser JK
Brain Behav Immun
July 13, 2022Distress Disorder Histories Relate to Greater Physical Symptoms Among Breast Cancer Patients and Survivors: Findings Across the Cancer Trajectory.
Renna ME, Shrout MR, Madison AA, Lustberg M, Povoski SP, Agnese DM, Reinbolt RE, Wesolowski R, Williams NO, Ramaswamy B, Sardesai SD, Noonan AM, VanDeusen JB, Stover DG, Cherian M, Malarkey WB, Di Gregorio M, Kiecolt-Glaser JK
Int J Behav Med
July 10, 2022Living with Advanced Breast Cancer: A Descriptive Analysis of Survivorship Strategies.
Grimm M, Radcliff L, Giles M, Nash R, Holley E, Panda S, Brophy L, Williams N, Cherian M, Stover D, Gatti-Mays ME, Wesolowski R, Sardesai S, Sudheendra P, Reinbolt R, Ramaswamy B, Pariser A
J Clin Med
May 24, 2022Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR
JAMA
May 19, 2022Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.
Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, theMednet.org NCI-CCC Tumor Board Program Collaborative Group , Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N
JMIR Cancer
April 8, 2022A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).
Leal TA, Sharifi MN, Chan N, Wesolowski R, Turk AA, Bruce JY, O'Regan RM, Eickhoff J, Barroilhet LM, Malhotra J, Mehnert J, Girda E, Wiley E, Schmitz N, Andrews S, Liu G, Wisinski KB
Cancer Med
April 7, 2022Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer - a review of current evidence for and against the use of anti-HER2 treatment regimens.
Johnson KC, Quiroga D, Sudheendra P, Wesolowski R
Expert Rev Anticancer Ther
April 7, 2022Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Telli ML, Tolaney SM, Shapiro GI, Middleton M, Lord SR, Arkenau HT, Tutt A, Abramson V, Dean E, Haddad TC, Wesolowski R, Ferrer-Playan J, Goddemeier T, Grombacher T, Dong J, Fleuranceau-Morel P, Diaz-Padilla I, Plummer R
NPJ Breast Cancer
April 1, 2022Breast cancer survivors' typhoid vaccine responses: Chemotherapy, obesity, and fitness make a difference.
Kiecolt-Glaser JK, Renna M, Peng J, Sheridan J, Lustberg M, Ramaswamy B, Wesolowski R, VanDeusen JB, Williams NO, Sardesai SD, Noonan AM, Reinbolt RE, Stover DG, Cherian MA, Malarkey WB, Andridge R
Brain Behav Immun
January 31, 2022Long-Term Follow-Up of Fractional CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors.
Quick AM, Hundley A, Evans C, Stephens JA, Ramaswamy B, Reinbolt RE, Noonan AM, Van Deusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Faubion SS, Loprinzi CL, Lustberg MB
J Clin Med
January 1, 2022Augmentation of Extracellular ATP Synergizes With Chemotherapy in Triple Negative Breast Cancer.
Manouchehri JM, Datta J, Willingham N, Wesolowski R, Stover D, Ganju RK, Carson WE, Ramaswamy B, Cherian MA
Front Oncol
October 1, 2021Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience.
Rinehardt H, Kassem M, Morgan E, Palettas M, Stephens JA, Suresh A, Ganju A, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Cherian M, Prieto Eibl MDPG, Miah A, Alnahhas I, Giglio P, Puduvalli VK, Ramaswamy B, Williams N, Noonan AM
Adv Psychosom Med
September 8, 2021Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer.
Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, Cherian M, Stover DG, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S
Breast Cancer Res Treat
May 26, 2021Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
Shapiro GI, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R, Yap TA
Br J Cancer
May 18, 2021Genomic features of rapid versus late relapse in triple negative breast cancer.
Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG
BMC Cancer
May 4, 2021Presentation and management of diverse cutaneous reactions after cyclin-dependent kinase (CDK) 4/6 inhibitor use.
Amigo M, Hoffman K, Chung C, Lustberg M, Wesolowski R, VanDeusen J, Stover D, Suarez GT, Cherian M, Kaffenberger B, Dulmage B
J Am Acad Dermatol
March 23, 2021Improving Breast Cancer Responses to Immunotherapy-a Search for the Achilles Heel of the Tumor Microenvironment.
Jenkins S, Wesolowski R, Gatti-Mays ME
Curr Oncol Rep
February 23, 2021LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
Dowlati A, Harvey RD, Carvajal RD, Hamid O, Klempner SJ, Kauh JSW, Peterson DA, Yu D, Chapman SC, Szpurka AM, Carlsen M, Quinlan T, Wesolowski R
Invest New Drugs
February 1, 2021Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy.
Quick AM, Zvinovski F, Hudson C, Hundley A, Evans C, Stephens JA, Arthur E, Ramaswamy B, Reinbolt RE, Noonan AM, VanDeusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Faubion SS, Loprinzi CL, Lustberg MB
Menopause
January 29, 2021Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W, Osborne C, Wesolowski R, Karuturi M, Conkling P, Bagley RG, Wang Y, Conlan MG, Kabos P
J Clin Oncol
January 7, 2021A solitary brain metastasis as the only site of recurrence of HR positive, HER2 negative breast cancer: a case report and review of the literature.
Patel SH, Saito YD, Li Z, Ramaswamy B, Stiff A, Kassem M, Wesolowski R
J Med Case Rep
January 1, 2021Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib.
Handy C, Wesolowski R, Gillespie M, Lause M, Sardesai S, Williams N, Grimm M, Kassem M, Ramaswamy B
Breast Cancer (Auckl)
January 1, 2021Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.
Sun SH, Benner B, Savardekar H, Lapurga G, Good L, Abood D, Nagle E, Duggan M, Stiff A, DiVincenzo MJ, Suarez-Kelly LP, Campbell A, Yu L, Wesolowski R, Howard H, Shah H, Kendra K, Carson WE
Front Immunol
January 1, 2021A Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility Study.
Zvinovski F, Stephens JA, Ramaswamy B, Reinbolt RE, Noonan AM, VanDeusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Mehta L, Foraker R, Gulati M, Lustberg M, Quick AM
J Oncol
November 5, 2020Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer.
Sardesai S, Sukumar J, Kassem M, Palettas M, Stephens J, Morgan E, Addison D, Baliga R, Stover DG, VanDeusen J, Williams N, Cherian M, Lustberg M, Wesolowski R, Ramaswamy B
Cardiooncology
November 2, 2020Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells.
Owen DH, Benner B, Pilcher C, Good L, Savardekar H, Norman R, Ghattas C, Shah M, Konda B, Verschraegen CF, Wesolowski R, Behbehani GK, Carson WE, Otterson GA
Clin Lung Cancer
November 1, 2020Worry and rumination in breast cancer patients: perseveration worsens self-rated health.
Renna ME, Rosie Shrout M, Madison AA, Lustberg M, Povoski SP, Agnese DM, Reinbolt RE, Wesolowski R, Williams NO, Ramaswamy B, Sardesai SD, Noonan AM, VanDeusen JB, Malarkey WB, Kiecolt-Glaser JK
J Behav Med
July 1, 2020Features, Outcomes, and Management Strategies of Male Breast Cancer: A Single Institution Comparison to Well-Matched Female Controls.
Liu J, Suresh A, Palettas M, Stephens J, Ganju A, Morgan E, Kassem M, Hou Y, Parwani A, Noonan A, Reinbolt R, VanDeusen J, Sardesai S, Williams N, Cherian M, Tozbikian G, Stover DG, Lustberg M, Li Z, Ramaswamy B, Wesolowski R
Abstr Euro J of Hum Gen
May 26, 2020Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B
Oncologist
May 19, 2020Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
Wesolowski R, Stiff A, Quiroga D, McQuinn C, Li Z, Nitta H, Savardekar H, Benner B, Ramaswamy B, Lustberg M, Layman RM, Macrae E, Kassem M, Williams N, Sardesai S, VanDeusen J, Stover D, Cherian M, Mace TA, Yu L, Duggan M, Carson WE
BMC Cancer
May 6, 2020Metastatic breast cancer patient perceptions of somatic tumor genomic testing.
Adams EJ, Asad S, Reinbolt R, Collier KA, Abdel-Rasoul M, Gillespie S, Chen JL, Cherian MA, Noonan AM, Sardesai S, VanDeusen J, Wesolowski R, Williams N, Shapiro CL, Macrae ER, Pilarski R, Toland AE, Senter L, Ramaswamy B, Lee CN, Lustberg MB, Stover DG
BMC Cancer
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Wesolowski has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- Celcuity
- Bristol Myers Squibb Foundation
Patient Comments
I am constantly amazed at the friendliness of the staff and doctors, I know they have very busy schedules, but appointments are never rushed, and all my questions are answered fully. You never ask if we the patients participate in the classes you offer, and I appreciate those also and really thank the PA suggesting them when I had my surgery as a way to get healthier. Thanks for all you do and know that I appreciate each and every one for being kind and helpful.
Feel a bit rushed during appointments so I miss opportunity to ask all of my questions but all of the "most important " items always get addressed.
Dr Wolosaski is very thorough. He spent as much time as I needed with him. He is thoughtful about questions he asks and thorough about what comes next.
Dr. Wesolowski is outstanding and I trust him. He always asks me what I think about my options and listens to my input.
I've had excellent care every time I have an appointment.
My oncologist, Dr. Robert Wesolowsky, and my Advanced Practice Nurse, Melissa Sullivan, are very knowledgeable and trustworthy. I believe I am in the best hands possible. The whole Spielman Center team--from receptionis to medical professionals to schedulers--are pleasant and focused on me as a person, not just a patient.
Felt like doctor was concerned about my well being and answered all questions.
I know Dr. Wesolowski is very busy with lots of patients to see, but I really wish he would slow down. I get more comprehensive info from the Resident, Dr. Stiff.
Everyone was so nice and explained everything about my diagnosis.